Subscribe to RSS - mail order diabetes supplies

mail order diabetes supplies

OIG: Handful of strips dominated Medicare mail-order market

 - 
01/16/2019

WASHINGTON – The top two strips accounted for 53% of the Medicare mail-order market, and the top 10 strips accounted for 98% of the market, according to a new report from the Office of Inspector General.

Extended bid contracts? ‘Either way you lose’

 - 
05/18/2018

YARMOUTH, Maine – If CMS decides to extend current competitive bidding contracts, a slight majority (53%) of respondents to a recent HME Newspoll say they would accept them—reluctantly.

Mail-order program creates 'vicious cycle'

 - 
02/21/2014

CHICAGO – Many national mail-order contract suppliers aren’t carrying the diabetes testing supplies beneficiaries get prescribed, says the American Association of Diabetes Educators (AADE).

Simplex refutes ‘No Call’ allegations

 - 
03/27/2013

NASHVILLE, Tenn. – A national provider of mail order diabetes supplies denies allegations that it has violated telemarketing laws in Missouri.

Level the playing field

 - 
02/25/2013

As a small business owner in the DME industry, I for one think it is about time CMS and Congress recognize the enormous disparity between mail order and non-mail order reimbursements (“Diabetes payments pushed off a cliff,” HME News, February 2013).

A winner reflects

 - 
11/26/2012

FLETCHER, N.C. – Marcus Suess won mail-order contracts for diabetes supplies in all nine competitive bidding areas in Round 1, but he says the jury’s still out on how well the program works—for providers and beneficiaries.

In brief: Few changes in new ASP figures

 - 
10/24/2012

BALTIMORE – The new average sales price (ASP) figures for nebulizer medications released in September brought few changes. Albuterol (J7613) was down 2 cents to 13 cents per dose, while budesonide (J7626) was down nearly 11 cents to about $4.87 per dose.

What happens to retail diabetes supplies under 15% cut?

 - 
08/31/2012

YARMOUTH, Maine – There's no official timetable, but it's unlikely CMS will drag its feet on pushing forward with its plan to use inherent reasonableness (IR) to reduce reimbursement for retail diabetes supplies, industry stakeholders say.

Retail diabetes: How low will CMS go?

 - 
07/27/2012

BALTIMORE – It was mail order vs. retail during last week's public hearing on inherent reasonableness (IR) for retail diabetes supplies, according to sources who attended the hearing.

Pages